UNASSIGNED: Blinatumomab is a @entity1075 /CD3 bispescific antibody designed to redirect T cells toward malignant B cells and induce their lysis. It recently gained accelerated approval by the FDA for the treatment of relapsed or refractory Philadelphia chromosome-negative @entity8625 (RR- @entity981 ). In the phase II trial that served as the basis for approval, blinatumomab demonstrated significant single-agent activity and induced remission [complete remission (CR) and CR with incomplete recovery of peripheral blood counts ( @entity6192 )] in 43% of 189 adult @entity1 with RR- @entity981 ; the majority of responders (82%) also attained negative minimal @entity66 ( @entity4145 (-)) status that did not generally translate into long-term remissions in most cases. Additional studies show that blinatumomab can induce high response rates associated with lasting remissions in @entity1 in first remission treated for @entity4145 positivity, suggesting a role for blinatumomab in the upfront, @entity4145 -positive setting. Blinatumomab infusion follows a predictable immunopharmacologic profile, including early cytokine release that can be associated with a clinical syndrome, T-cell expansion, and B-cell depletion. @entity137 represent a unique @entity137 that shares similarities with adverse effects of other T-cell engaging therapies. Further studies are needed to clarify the optimal disease setting and timing for blinatumomab therapy. Additional insights into the pathogenesis, risk factors, and prevention of @entity137 as well as a better understanding of the clinical consequences and biologic pathways that are associated with drug resistance are needed. Clin Cancer Res; 21(19); 1-8.   2015 AACR.

Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Neurologic toxicities', 'neurologic toxicities'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity1075 :: ('930', 'Gene') :: ['CD19'] @entity8625 :: ('MESH:D015456', 'Disease') :: ['B-cell acute lymphoblastic leukemia'] @entity6192 :: ('1392', 'Gene') :: ['CRh'] @entity4145 :: ('MESH:C537373', 'Disease') :: ['MRD']
@entity8625 :: (MESH:D015456,Disease) :: ['B-cell Acute Lymphoblastic Leukemia']
